Zypitamag Now Available for $1.15 per Day*!

No insurance needed
Only through Marley Drug

Marley Drug gives certainty, reliability, and price transparency

With Marley Drug you can be CERTAIN that your patients will get Zypitamag for $1.15 per pill*.

Available to all patients*

  • No insurance or co-pay needed
  • No prior authorization, No step-therapy
  • No savings card/copay programs


  • Free shipping nationwide
  • Patients get the first 30 days free with a valid Rx*!
* Conditions apply. See below for more information.

What is Marley Drug?

Marley Drug is a forward thinking pharmacy that offers over 400 generic drugs at low costs, and now branded Zypitamag (pitavastatin) tablets. Marley Drug believes that no one should wait in line for over 20 minutes to have their prescription, only to leave without their medication due to outrageously overpriced drugs.

E-scribe Zypitamag

Patient is contacted

Free delivery to patient

How to fill prescriptions through Marley Drug

E-Scribe through Marley Drug located in North Carolina.

Once Marley Drug receives the prescription, they will call your patient to arrange for payment. All packages are shipped priority mail and should be received within three business days.

Not using EMR yet? No problem. You can fax your prescription to 336-771-9921 or call it in to 1-800-286-6781.

Want Resources? If you would like some informational materials for your lobby or exam rooms let us know! Email us at zypitamag@medicure.com, fill out the contact us form, or just have your office manager give us a call at 1-800-509-0544.

How to Get your Patients Zypitamag through Marley Drug

Details and Criteria to Access Zypitamag For $1.15 per day through Marley Drug

This offer is valid for eligible patients purchasing ZYPITAMAG and may not be used for any other product. This offer is valid for the purchase of ZYPITAMAG manufactured for Medicure and lawfully purchased from Marley Drug located in North Carolina (5008 Peters Creek Pkwy, Winston-Salem, NC 27127, United States). This offer is valid for patients being treated with ZYPITAMAG for an FDA-approved indication who are 18 years of age or older. Patients will be charged $1.15 per day for every day listed in their prescription. For example, 30 pills over 30 days will cost $34.50. Patients will be charged a minimum $34.50 per 30 day fill because of costs incurred for shipping and handling. This offer must not be combined with any insurance coverage. Patients using insurance to pay for their Zypitamag prescription are not eligible for this offer. Patients must not apply any out-of-pocket expenses incurred using this Savings Offer toward any insurance benefit. All Program payments are for the benefit of the patient only. The patient is responsible for applicable taxes, if any. This offer is not conditioned on any past, present, or future purchase, including refills. Offer not valid where prohibited by law or restricted. This offer is non-transferable, is limited to one per person, and may not be combined with any other offer. The 30-day free fill is limited to one person as a one time use. Offer must be presented along with a valid prescription for ZYPITAMAG at the time of purchase. Marley Drug reserves the right to change or discontinue this offer at any time without notice.



ZYPITAMAG is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with primary hyperlipidemia.

Pediatric use information is approved for Kowa Co Ltd LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd marketing exclusivity rights, this drug product is not labeled with that information.


ZYPITAMAG is contraindicated in the following conditions:

  • Concomitant use of cyclosporine.
  • Acute liver failure or decompensated cirrhosis.
  • Hypersensitivity to pitavastatin or any excipients in ZYPITAMAG. Hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin.


  • Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher ZYPITAMAG dosage. ZYPITAMAG is contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil. The following drugs when used concomitantly with ZYPITAMAG may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (>1 g/day), fibrates, and colchicine. Discontinue ZYPITAMAG if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Temporarily discontinue ZYPITAMAG in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis; e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the ZYPITAMAG dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever.
  • Immune-Mediated Necrotizing Myopathy (IMNM): There have been rare reports of IMNM, an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue ZYPITAMAG if IMNM is suspected.
  • Hepatic Dysfunction: Increases in serum transaminases can occur. Rare postmarketing reports of fatal and non-fatal hepatic failure have occurred. Consider liver enzyme testing before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue ZYPITAMAG.
  • Increases in HbA1c and Fasting Serum Glucose Levels: Increases of each have been reported with statins, including ZYPITAMAG. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.

ADVERSE REACTIONS: The most frequent adverse reactions (rate ≥ 2%) are myalgia, constipation, diarrhea, back pain, and pain in extremity. This is not a complete list of all reported adverse events.

For additional information, refer to full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Unite Interactive